Release
📈 Stocks
AusperBio Reports 15-Month Functional Cure Durability for AHB-137 in CHB
(2 days ago)
AusperBio's AHB-137 shows sustained functional cure in chronic hepatitis B patients for up to 15 months post-treatment, bolstering the company's Phase 3…